Table 2.
PrEP uptake preferences and PrEP awareness predicted by the PrEP concerns among men participated in the China MSMs HIV PrEP Uptake Willingness Online Survey, 2017 (N = 4581)
| Total (N = 4581) | Heard of PrEP | PrEP uptake preferences | ||||||
|---|---|---|---|---|---|---|---|---|
| Yes (%) (n = 1028) | No (%) (n = 3553) | χ² p value | Definitely yes (%) (n = 1191) | Probably yes (%) (n = 2274) | No (%) (n = 1116) | χ²p value | ||
| PrEP uptake preferences | <0.001 | |||||||
| Yes | 1191 (26.0) | 335 (32.6) | 856 (24.1) | |||||
| Maybe | 2274 (49.6) | 486 (47.3) | 1788 (50.3) | |||||
| No | 1116 (24.4) | 207 (20.1) | 909 (25.6) | |||||
| Heard of PrEP | <0.001 | |||||||
| Yes | 1028 (22.4) | 335 (28.1) | 486 (21.4) | 207 (18.5) | ||||
| No | 3553 (77.6) | 856 (71.9) | 1788 (78.6) | 909 (81.5) | ||||
| Preferences on where to get PrEP | 0.294 | |||||||
| Medical facilities | 713 (15.5) | 221 (21.5) | 492 (13.8) | <0.001 | 249 (20.9) | 464 (20.4) | ||
| Pharmacies/Internet pharmacies/vending machine | 2121 (46.3) | 452 (44.0) | 1669 (47.0) | 710 (59.6) | 1411 (62.0) | |||
| Gay communities | 581 (12.7) | 138 (13.4) | 443 (12.5) | 210 (17.6) | 371 (16.3) | |||
| Others | 1166 (25.5) | 217 (21.1) | 949 (26.7) | 22 (1.8) | 28 (1.2) | |||
| Concerns about PrEP | ||||||||
| Perceived risk of HIV | 0.102 | <0.001 | ||||||
| Low | 903 (19.7) | 221 (21.5) | 682 (19.2) | 143 (12.0) | 408 (17.9) | 352 (31.5) | ||
| High | 3678 (80.3) | 807 (78.5) | 2871 (80.8) | 1048 (88.0) | 1866 (82.1) | 764 (68.5) | ||
| Doubts on PrEP's efficacy | <0.001 | 0.061 | ||||||
| Yes | 2604 (56.8) | 514 (50.0) | 2090 (58.8) | 646 (54.2) | 1328 (58.4) | 630 (56.5) | ||
| No | 1977 (43.2) | 514 (50.0) | 1463 (41.2) | 545 (45.8) | 946 (41.6) | 486 (43.5) | ||
| Worry about PrEP's side effects | 0.476 | <0.001 | ||||||
| Yes | 3203 (69.9) | 728 (70.8) | 2475 (69.7) | 803 (67.4) | 1661 (73.0) | 739 (66.2) | ||
| No | 1378 (30.1) | 300 (29.2) | 1078 (30.3) | 388 (32.6) | 613 (27.0) | 377 (33.8) | ||
| Financial burden | 0.036 | <0.001 | ||||||
| Yes | 2048 (44.7) | 489 (47.6) | 1559 (43.9) | 602 (50.5) | 1005 (49.1) | 441 (39.5) | ||
| No | 2533 (55.3) | 539 (52.4) | 1994 (56.1) | 589 (49.5) | 1269 (50.1) | 675 (60.5) | ||
| Have no access to PrEP | 0.001 | <0.001 | ||||||
| Yes | 1954 (42.7) | 393 (38.2) | 1561 (43.9) | 588 (49.4) | 973 (42.8) | 393 (35.2) | ||
| No | 2627 (57.3) | 635 (61.8) | 1992 (56.1) | 603 (50.6) | 1301 (57.2) | 723 (64.8) | ||
| Inconvenience in taking PrEP everyday | 0.554 | 0.565 | ||||||
| Yes | 1078 (23.5) | 249 (24.2) | 829 (23.3) | 281 (23.6) | 547 (24.1) | 250 (22.4) | ||
| No | 3503 (76.5) | 779 (75.8) | 2724 (76.7) | 910 (76.4) | 1727 (75.9) | 866 (77.6) | ||
| Prefer using condom as protection for HIV | 0.050 | <0.001 | ||||||
| Yes | 1734 (37.9) | 416 (40.5) | 1318 (37.1) | 321 (27.0) | 889 (39.1) | 524 (47.0) | ||
| No | 2847 (62.1) | 612 (59.5) | 2235 (62.9) | 870 (73.0) | 1385 (60.9) | 592 (53.0) | ||
MSM, men who have sex with men; χ2, Chi‐squared test; HIV, human immunodeficiency virus; PrEP, pre‐exposure prophylaxis.